HRP20201221T1 - Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu - Google Patents
Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu Download PDFInfo
- Publication number
- HRP20201221T1 HRP20201221T1 HRP20201221TT HRP20201221T HRP20201221T1 HR P20201221 T1 HRP20201221 T1 HR P20201221T1 HR P20201221T T HRP20201221T T HR P20201221TT HR P20201221 T HRP20201221 T HR P20201221T HR P20201221 T1 HRP20201221 T1 HR P20201221T1
- Authority
- HR
- Croatia
- Prior art keywords
- parts
- composition
- use according
- acid
- amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 11
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000653 nervous system Anatomy 0.000 title 1
- 229940012843 omega-3 fatty acid Drugs 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 title 1
- 239000006014 omega-3 oil Substances 0.000 title 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 11
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 5
- 210000001328 optic nerve Anatomy 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/08—Food product presented as a kit of parts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Claims (10)
1. Sastav ili komplet dijelova koji sadrži najmanje 3 g eikosapentaenske kiseline i koji sadrži dokozaheksaenoinsku kiselinu u masenom omjeru EPA: DHA od 1: 1 do 5: 1, za upotrebu u liječenju, poboljšanju ili sprečavanju oštećenja optičkog živca u pacijenta, pri čemu količina primijenjene EPA iznosi najmanje 3 g dnevno.
2. Sastav ili komplet dijelova za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je oštećenje optičkog živca odabrano iz skupine koja se sastoji od oštećenja optičkog živca zbog glaukoma, ishemijske optičke neuropatije (ION) i optičkog neuritisa, ili bilo koje njihove kombinacije.
3. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 2, naznačen time da oštećenje optičkog živca uzrokuje optički neuritis.
4. Sastav ili komplet dijelova za uporabu prema zahtjevu 1, naznačen time, da se upotrebljava u liječenju, poboljšanju ili prevenciji glaukoma.
5. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se količina eikosapentaenske kiseline i dokozaheksaenske kiseline nalazi između 5 g do 15 g na dan.
6. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da unesena količina eikosapentaenske kiseline i dokozaheksaenske kiseline prelazi 7,5 g na dan.
7. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se dana količina eikosapentaenske kiseline i dokozaheksaenske kiseline nalazi između 7,5 g do 10 g na dan.
8. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, što je pripravak farmaceutski sastav ili je dio dijela farmaceutski kompleta dijelova.
9. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, što je pripravak prehrambeni pripravak ili komplet dijelova koji predstavljaju prehrambeni komplet dijelova.
10. Sastav ili komplet dijelova za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time, da je količina eikosapentaenske kiseline i dokozaheksanojske kiseline takva da je omjer mase arahidonske kiseline / eikosapentaenojske kiseline u krvi u rasponu od 0,8 do 3, poželjno od 1 do 1,5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/077356 WO2015090394A1 (en) | 2013-12-19 | 2013-12-19 | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
| EP13830184.1A EP3082795B1 (en) | 2013-12-19 | 2013-12-19 | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201221T1 true HRP20201221T1 (hr) | 2020-11-13 |
Family
ID=50137601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201221TT HRP20201221T1 (hr) | 2013-12-19 | 2020-08-04 | Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160331712A1 (hr) |
| EP (1) | EP3082795B1 (hr) |
| JP (1) | JP6389893B2 (hr) |
| KR (1) | KR101898358B1 (hr) |
| CN (1) | CN105828813A (hr) |
| AU (1) | AU2013407946B2 (hr) |
| BR (1) | BR112016014182A2 (hr) |
| CA (1) | CA2934600C (hr) |
| CY (1) | CY1123942T1 (hr) |
| DK (1) | DK3082795T3 (hr) |
| ES (1) | ES2813383T3 (hr) |
| HR (1) | HRP20201221T1 (hr) |
| HU (1) | HUE050205T2 (hr) |
| IL (1) | IL246254B (hr) |
| LT (1) | LT3082795T (hr) |
| MX (1) | MX2016007803A (hr) |
| MY (1) | MY185412A (hr) |
| PH (1) | PH12016501159A1 (hr) |
| PL (1) | PL3082795T3 (hr) |
| PT (1) | PT3082795T (hr) |
| RS (1) | RS60862B1 (hr) |
| RU (1) | RU2667640C1 (hr) |
| UA (1) | UA117274C2 (hr) |
| WO (1) | WO2015090394A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| CN108721269A (zh) * | 2018-07-10 | 2018-11-02 | 广东海洋大学 | 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用 |
| CN114786480B (zh) * | 2019-10-30 | 2024-03-29 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| IL294873A (en) | 2020-02-06 | 2022-09-01 | Perfuse Therapeutics Inc | Preparations for the treatment of eye diseases |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| US20100254951A1 (en) * | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
| EP1852499A4 (en) * | 2005-02-22 | 2009-05-06 | Mochida Pharm Co Ltd | AGENT PROMOTING NEUROTISATION |
| WO2007081773A2 (en) * | 2006-01-05 | 2007-07-19 | Reliant Pharmaceuticals, Inc | Treatment of fatty liver |
| EP1900378A1 (en) | 2006-08-31 | 2008-03-19 | Novartis AG | Pharmaceutical compositions for the treatment of fungal infections |
| WO2010018856A1 (ja) * | 2008-08-13 | 2010-02-18 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防／改善または治療剤 |
| EP2429317B2 (en) * | 2009-04-17 | 2019-02-20 | Natac Pharma, S.L. | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
| JP2014504605A (ja) * | 2011-01-25 | 2014-02-24 | ネステク ソシエテ アノニム | 動物の視覚系の劣化を治療、緩和又は予防するための方法及び組成物 |
| WO2012112340A2 (en) * | 2011-02-18 | 2012-08-23 | Nestec S.A. | Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| JP2016508955A (ja) * | 2011-09-12 | 2016-03-24 | ジョルジオ タソスＧＥＯＲＧＩＯＵ， Ｔａｓｓｏｓ | 疾病治療用オメガ脂肪酸の使用 |
-
2013
- 2013-12-19 BR BR112016014182A patent/BR112016014182A2/pt not_active Application Discontinuation
- 2013-12-19 HU HUE13830184A patent/HUE050205T2/hu unknown
- 2013-12-19 MX MX2016007803A patent/MX2016007803A/es unknown
- 2013-12-19 WO PCT/EP2013/077356 patent/WO2015090394A1/en active Application Filing
- 2013-12-19 EP EP13830184.1A patent/EP3082795B1/en active Active
- 2013-12-19 RS RS20200971A patent/RS60862B1/sr unknown
- 2013-12-19 RU RU2016129079A patent/RU2667640C1/ru active
- 2013-12-19 MY MYPI2016702245A patent/MY185412A/en unknown
- 2013-12-19 CN CN201380081739.3A patent/CN105828813A/zh active Pending
- 2013-12-19 KR KR1020167019609A patent/KR101898358B1/ko active IP Right Grant
- 2013-12-19 PT PT138301841T patent/PT3082795T/pt unknown
- 2013-12-19 PL PL13830184T patent/PL3082795T3/pl unknown
- 2013-12-19 LT LTEP13830184.1T patent/LT3082795T/lt unknown
- 2013-12-19 CA CA2934600A patent/CA2934600C/en active Active
- 2013-12-19 UA UAA201607999A patent/UA117274C2/uk unknown
- 2013-12-19 DK DK13830184.1T patent/DK3082795T3/da active
- 2013-12-19 US US15/106,475 patent/US20160331712A1/en not_active Abandoned
- 2013-12-19 AU AU2013407946A patent/AU2013407946B2/en active Active
- 2013-12-19 JP JP2016540609A patent/JP6389893B2/ja active Active
- 2013-12-19 ES ES13830184T patent/ES2813383T3/es active Active
-
2016
- 2016-06-15 PH PH12016501159A patent/PH12016501159A1/en unknown
- 2016-06-15 IL IL246254A patent/IL246254B/en active IP Right Grant
-
2018
- 2018-05-11 US US15/977,354 patent/US10905671B2/en active Active
-
2020
- 2020-08-04 HR HRP20201221TT patent/HRP20201221T1/hr unknown
- 2020-08-13 CY CY20201100758T patent/CY1123942T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016014182A2 (pt) | 2017-08-08 |
| UA117274C2 (uk) | 2018-07-10 |
| JP2017501169A (ja) | 2017-01-12 |
| RS60862B1 (sr) | 2020-11-30 |
| PL3082795T3 (pl) | 2020-11-16 |
| PT3082795T (pt) | 2020-08-27 |
| DK3082795T3 (da) | 2020-08-24 |
| US10905671B2 (en) | 2021-02-02 |
| CN105828813A (zh) | 2016-08-03 |
| JP6389893B2 (ja) | 2018-09-12 |
| CA2934600A1 (en) | 2015-06-25 |
| RU2667640C1 (ru) | 2018-09-21 |
| RU2016129079A (ru) | 2018-01-24 |
| KR101898358B1 (ko) | 2018-09-12 |
| KR20160093729A (ko) | 2016-08-08 |
| EP3082795B1 (en) | 2020-05-20 |
| MY185412A (en) | 2021-05-18 |
| AU2013407946A1 (en) | 2016-08-04 |
| MX2016007803A (es) | 2017-08-10 |
| HUE050205T2 (hu) | 2020-11-30 |
| WO2015090394A1 (en) | 2015-06-25 |
| IL246254B (en) | 2021-04-29 |
| CA2934600C (en) | 2018-11-20 |
| US20160331712A1 (en) | 2016-11-17 |
| LT3082795T (lt) | 2020-11-10 |
| AU2013407946A2 (en) | 2016-08-25 |
| ES2813383T3 (es) | 2021-03-23 |
| US20190192466A1 (en) | 2019-06-27 |
| IL246254A0 (en) | 2016-07-31 |
| PH12016501159A1 (en) | 2016-08-15 |
| EP3082795A1 (en) | 2016-10-26 |
| AU2013407946B2 (en) | 2017-09-07 |
| CY1123942T1 (el) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201221T1 (hr) | Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu | |
| CL2019001686A1 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas. | |
| NZ729290A (en) | Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism | |
| CL2017001614A1 (es) | Proceso para aumentar la estabilidad de una composición que comprende ácidos grasos omega-3 poliinsaturados | |
| WO2009091538A8 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
| IN2014DN08449A (hr) | ||
| JP2016512245A5 (ja) | マイボーム腺を標的とする組成物 | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| IN2014DN06125A (hr) | ||
| HRP20191963T1 (hr) | Smjesa masnih kiselina za primjenu u liječenju upalnih patologija | |
| WO2012013331A3 (en) | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases | |
| AR110777A1 (es) | Ácidos indanilaminopirazinilciclopropancarboxílicos composiciones farmacéuticas y sus usos en el tratamiento de enfermedades mediadas por gpr40 | |
| AR061622A1 (es) | Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| JP2014505702A5 (hr) | ||
| MX2020002238A (es) | Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias. | |
| BR112015005942A2 (pt) | extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica | |
| BR112015029897A2 (pt) | composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição | |
| WO2017077528A3 (en) | Methods and pharmaceutical compositions for treatment of lung inflammation | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| BR112018001164A2 (pt) | composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular | |
| TR201903470T4 (tr) | Kişisel hijyen için formülasyon. | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| UA111967C2 (uk) | Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання | |
| MY194044A (en) | Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products |